...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of infection and public health. >Intermittent vs. continuous vancomycin infusion for gram-positive infections: A systematic review and meta-analysis
【24h】

Intermittent vs. continuous vancomycin infusion for gram-positive infections: A systematic review and meta-analysis

机译：间歇性与连续万古霉素输注革兰阳性感染：系统审查和荟萃分析

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective The clinical use of intermittent infusion of vancomycin (IIV) and continuous infusion of vancomycin (CIV) is controversial. The aim of this study was to assess the effectiveness and safety of IIV and CIV by using a meta-analysis for cohort studies and randomized controlled trials. Methods We compared the probabilities of target attainment (PTA) for the measured concentration (Csubm/sub) ≥the target concentration (Csubt/sub), the PTA for the area under the drug concentration curve/minimal inhibitory concentration (AUC/MIC) ≥400, the duration of treatment, nephrotoxicity, and overall mortality after vancomycin treatment as reported in PubMed, Embase, Cochrane, and Web of Science. Results A total of 14 studies with 1640 patients were included in the meta-analysis. For IIV, the PTA of Csubm/sub?≥?Csubt/sub (RR?=?0.72, 95% CI?=?0.60–0.88), and nephrotoxicity (RR?=?1.70, 95% CI?=?1.34–2.14) were significantly different from those of CIV. The treatment duration (SMD?=?0.08, 95% CI?=??0.08–0.25), the PTA of AUC/MIC ≥ 400 (RR?=?0.84, 95% CI?=?0.70–1.00) and mortality (RR?=?0.94, 95% CI?=?0.72–1.25) were not significantly different from those of CIV. Conclusions The results showed that CIV was easier to achieve Csubt/sub and safer than IIV. Additional randomized controlled trials focusing on the concentration of vancomycin are needed for further analysis.
机译：目的临床应用激增的万古霉素（IIV）（IIV）和万古霉素（CIV）的连续输注是有争议的。本研究的目的是通过使用队列研究和随机对照试验的荟萃分析来评估IIV和CIV的有效性和安全性。方法与测量浓度（C M ）≥靶浓度（C T ），PTA用于药物下的靶浓度（C t ）的方法浓度曲线/最小抑制浓度（AUC / MIC）≥400，治疗持续时间，肾病素治疗后的治疗后，如PubMed，Embase，Cochrane和Science网上报道。结果荟萃分析中共有1640名患者的14项研究。对于IIV，C m 的pta≥？c t （rr？= 0.72,95％ci？= 0.60-0.88）和肾毒性（RR？ =？1.70,95％CI？=？1.34-2.14）与文明的不同。治疗持续时间（SMD？= 0.08,95％CI？= ?? 0.08-0.25），AUC /MIC≥400的PTA（RR？= 0.84,95％CI？=？0.70-1.00）和死亡率（ RR？=？0.94,95％CI？=？0.72-1.25）与文明的不同没有显着不同。结论结果表明，文明更容易实现C T 比IIV更安全。需要额外的随机对照试验，用于进一步分析需要进行的含量浓度的万古霉素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号